Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eniluracil

Next Previous
Drug Profile

Eniluracil

Alternative Names: 5-Ethynyluracil; 5-EU; 776C85; ADH 300004; GW 776C85

Latest Information Update: 17 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Adherex Technologies; Fennec Pharmaceuticals; GlaxoSmithKline
  • Class Antineoplastics; Chemosensitisers; Pyrimidinones; Small molecules
  • Mechanism of Action Dihydropyrimidine dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Breast cancer
  • Discontinued Colorectal cancer; Erythrodysaesthesia; Head and neck cancer; Liver cancer; Pancreatic cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 03 Sep 2014 Adherex is now called Fennec Pharmaceuticals
  • 09 Aug 2013 Eniluracil is available for licensing as of 09 Aug 2013. www.adherex.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top